Nanocapsule-mediated cytosolic siRNA delivery for anti-inflammatory treatment

    loading  Checking for direct PDF access through Ovid


The use of nanoparticle-stabilized nanocapsules for cytosolic siRNA delivery for immunomodulation in vitro and in vivo is reported. These NPSCs deliver siRNA directly to the cytosol of macrophages in vitro with concomitant knockdown of gene expression. In vivo studies showed directed delivery of NPSCs to the spleen, enabling gene silencing of macrophages, with preliminary studies showing 70% gene knockdown at a siRNA dose of 0.28 mg/kg. Significantly, the delivery of siRNA targeting tumor necrosis factor-α efficiently silenced TNF-α expression in LPS-challenged mice, demonstrating efficacy in modulating immune response in an organ-selective manner. This research highlights the potential of the NPSC platform for targeted immunotherapy and further manipulation of the immune system.

Graphical abstract

Nanoparticle-stabilized nanocapsules (NPSCs) are used to deliver TNF-α targeted siRNA for inflammation therapy. NPSC siRNA delivery effectively prevents cytokine production in LPS-stimulated mice.

Related Topics

    loading  Loading Related Articles